Download MendeleyDiscovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach
Kamada, Y., Sakai, N., Sogabe, S., Ida, K., Oki, H., Sakamoto, K., Lane, W., Snell, G., Iida, M., Imaeda, Y., Sakamoto, J., Matsui, J.(2017) J Med Chem 60: 4358-4368
- PubMed: 28471657
- DOI: https://doi.org/10.1021/acs.jmedchem.7b00313
- Primary Citation of Related Structures:
5X4M, 5X4N, 5X4O, 5X4P, 5X4Q - PubMed Abstract:
B-cell lymphoma 6 (BCL6) is a transcriptional factor that expresses in lymphocytes and regulates the differentiation and proliferation of lymphocytes. Therefore, BCL6 is a therapeutic target for autoimmune diseases and cancer treatment. This report presents the discovery of BCL6-corepressor interaction inhibitors by using a biophysics-driven fragment-based approach. Using the surface plasmon resonance (SPR)-based fragment screening, we successfully identified fragment 1 (SPR K D = 1200 μM, ligand efficiency (LE) = 0.28), a competitive binder to the natural ligand BCoR peptide. Moreover, we elaborated 1 into the more potent compound 7 (SPR K D = 0.078 μM, LE = 0.37, cell-free protein-protein interaction (PPI) IC 50 = 0.48 μM (ELISA), cellular PPI IC 50 = 8.6 μM (M2H)) by a structure-based design and structural integration with a second high-throughput screening hit.
Organizational Affiliation:
Takeda Pharmaceutical Company Limited , 26-1 Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-8555, Japan.
